No Data
No Data
Tenax Therapeutics | 10-Q: Quarterly report
Express News | Tenax Therapeutics Q1 EPS $(3.12) Misses $(2.40) Estimate
Express News | Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics 1Q Loss/Shr $3.12 >TENX
Tenax Therapeutics 1Q Loss/Shr $3.12 >TENX
Express News | Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Express News | Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)
No Data